PHARMACOKINETICS OF FINGOLIMOD AND METABOLITES IN SUBJECTS WITH SEVERE RENAL IMPAIRMENT: AN OPEN-LABEL, SINGLE-DOSE, PARALLEL-GROUP STUDY ArticleDavid O.J., Pryce M., Meiser K., Picard F., Emotte C., Kobalava Z., Moiseev V., Schmouder R.International Journal of Clinical Pharmacology and Therapeutics. Vol. 53. 2015. P.. 547-854